-
01:41:06 PM

SVA - Sinovac Biotech, Ltd.

12/09/20 7:30 AM
Nasdaq : SVA
Sinovac Announces Product License for 23-Valent Pneumococcal Polysaccharide Vaccine
Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration (NMPA) has approved and issued a Product license for the Company's 23-Valent Pneumococcal Polysaccharide ("PPV") Vaccine to prevent the infection by streptococcus pneumonia in adults and children ages 2 years old and above. Mr. Weidong Yin, Chairman, President and CEO of Sinova
RHEA-AI
neutral
12/07/20 7:30 AM
Nasdaq : SVA
Sinovac Reports Unaudited Third Quarter 2020 Financial Results
Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the third quarter ended September 30, 2020. Third Quarter and Nine Months Ended 2020 Financial Summary Sales for the third quarter of 2020 were $115.5 million, an increase of 79.4% from $64.3 million in the prior year period. Sales for the nine months ended September 30, 2020, were $183.2 million
RHEA-AI
neutral
12/06/20 6:30 PM
Nasdaq : SVA
Sinovac Secures Approximately $500 Million in Funding for COVID-19 Vaccine Development
Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that Sinovac Life Sciences Co., Ltd. ("Sinovac LS") (formerly known as Sinovac Research and Development Co., Ltd.), a subsidiary of Sinovac, has secured approximately US$500 million in funding for further development, capacity expansion and manufacturing of the CoronaVac, its COVID-19 vaccine candidate, as well as conduct other dev
RHEA-AI
neutral
09/28/20 8:30 AM
Nasdaq : SVA
Beijing Fourth Intermediate People's Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan
Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that the Fourth Intermediate People's Court of Beijing ("Beijing Fourth Court") issued a judgement holding Sinobioway Bio-medicine Co., Ltd. ("Sinobioway Medicine") and Mr. Aihua Pan (collectively, "the Defendants") liable for torts and breaches of shareholder fiduciary duty. The judgment follows a complaint filed by Sinovac Biotech
RHEA-AI
very negative